Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines

International Journal of Cancer

Volumn 99, Issue 4, 2002, Pages 538-548

  Bancroft, Caren C ^a   Chen, Zhong ^a   Yeh, Jason ^a   Sunwoo, John B ^a   Yeh, Ning T ^a   Jackson, Sadhana ^a   Jackson, Chad ^a   Van Waes, Carter ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

AP 1; EGFR; HNSCC; IL 8; MEK; NF B; PI3K; VEGF

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RECOMBINANT EPIDERMAL GROWTH FACTOR; TRANSCRIPTION FACTOR AP 1; UO 126; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; ENDOTHELIAL GROWTH FACTORS; ENZYME ACTIVATION; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK NEOPLASMS; IMMUNOBLOTTING; INTERLEUKIN-8; LUCIFERASES; LYMPHOKINES; MAP KINASE KINASE KINASE 1; MODELS, BIOLOGICAL; NF-KAPPA B; PRECIPITIN TESTS; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTOR AP-1; TRANSFECTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036605053     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10398     Document Type: Article

References (58)

1. Transfection of interleukin-8 increases angiogenesis and tumorigenesis of human gastric carcinoma cells in nude mice
2. Growth regulated oncogene-α expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism
3. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, metastasis and angiogenesis
4. Effects of interleukin-1alpha, interleukin-1 receptor antagonist, and neutralizing antibody on proinflammatory cytokine expression by human squamous cell carcinoma lines
5. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer
6. Constitutive activation of transcription factors NF-κB, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and proangiogenic cytokines
7. Expression of a dominant-negative mutant inhibitor-κBα of nuclear factor-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo
8. The host environment promotes the constitutive activation of nuclear factor-kappaB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma
9. Novel proteasome inhibitor PS-341 inhibits activation of NF-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma
10. Co-expression of pro-angiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves co-activation by MEK-MAPK and IKK-NF-κB signal pathways
11. IL (Interleukin)-1α promotes nuclear factor-κB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinoma
12. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K pathways contributes to expression of proangiogenic cytokines IL-8 and VEGF in head and neck squamous cell carcinoma
13. Expression of proangiogenic chemokine Gro 1 in low and high metastatic variants of Pam murine squamous cell carcinoma is differentially regulated by IL-1a, EGF and TGF-b1 through NF-κB dependent and independent mechanisms
14. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer
15. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck
16. Epidermal growth factor-related peptides and their receptors in human malignancies
17. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification
18. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival
19. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells
20. Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation
21. Transforming growth factor alpha and mouse models of human breast cancer
22. The EGF receptor family as targets for cancer therapy
23. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells
24. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
25. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
26. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
27. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer
28. The signaling pathway coupling epidermal growth factor receptors to activation of p21ras
29. Phosphatidyl inositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association
30. The mitogen-activated protein kinase signal transduction pathway
31. An epidermal growth factor receptor/Jak2 tyrosine kinase domain chimera induces tyrosine phosphorylation of Stat5 and transduces a growth signal in hematopoietic cells
32. Phosphorylation of c-jun mediated by MAP kinases
33. Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-kappaB activation
34. Induction of NF-κB by the Akt/PKB kinase
35. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro
36. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo
37. Human squamous cell carcinoma. Establishment and characterization of new permanent cell lines
38. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner
39. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
40. Identification of a novel inhibitor of mitogen-activated protein kinase kinase
41. Akt is a direct target of phosphatidyl 3-kinase
42. Akt suppresses apoptosis by stimulating the transcription potential of the RelA/p65 subunit of NF-κB
43. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation
44. Epidermal growth factor-induced nuclear factor KB activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells
45. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN
46. Tumor necrosis factor alpha and interferon gamma synergistically induce interleukin-8 production in a human gastric cancer cell line through acting concurrently on AP-1 and NF-κB-like binding sites of the interleukin-8 gene
47. Human T-cell leukemia virus type I Tax transactivates human interleukin 8 gene through acting concurrently on AP-1 and nuclear factor-kappaB-like sites
48. Cooperation between transcription factor AP-1 and NF-kappaB in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia
49. Ets1, NF-κB AP-1 synergistically transactivate the human GM-CSF promoter
50. Induced expression of dominant negative c-jun downregulates NfkappaB and AP-1 target genes and suppresses the tumor phenotype in human keratinocytes
51. Transformation nonresponsive cells owe their resistance to lack of p65/nuclear factor-kappaB activation
52. Functional cooperation between JunD and NF-κB in rat hepatocytes
53. Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes
54. Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer
55. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8
56. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma
57. Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-kappaB
58. Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cDNA microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis, and the NF-kappaB signal pathway